Stay updated on APL-2 in wAIHA/CAD Safety, Efficacy Clinical Trial
Sign up to get notified when there's something new on the APL-2 in wAIHA/CAD Safety, Efficacy Clinical Trial page.

Latest updates to the APL-2 in wAIHA/CAD Safety, Efficacy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page adds a new release note: Revision: v3.4.2. The administrative notice about government funding and operating status has been removed, along with a previous release note Revision: v3.4.1.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added, and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedUI updates include a glossary display option and updated policy/QC labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) with older labels removed. These changes do not affect the study details, eligibility criteria, or results.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4. This is a minor version update and does not affect the study information or how users interact with the page.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a consolidated Locations section listing study sites by state (California, Florida, Iowa, Minnesota, North Carolina, Tennessee, Washington) and removed the prior per-state location headings.SummaryDifference0.8%

- Check92 days agoChange DetectedThe Publications description in the Study Details section was updated to specify that publications are automatically filled from PubMed, with a revision label showing v3.3.2; the previous text described PubMed-derived publications and listed an older revision (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to APL-2 in wAIHA/CAD Safety, Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 in wAIHA/CAD Safety, Efficacy Clinical Trial page.